Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07401537

Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer

Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer: A Multicenter Randomized Controlled Clinical Trial

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions Breast Cancer Triple -Negative Breast Cancer

Interventions Extended-Dose Interval Immunotherapy Standard-Dose Interval Immunotherapy

Updated 1 time since 2026 Last updated: Feb 6, 2026 Started: Dec 31, 2025 Primary completion: Dec 31, 2028 Completion: Dec 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and Triple -Negative Breast Cancer and is currently actively recruiting participants. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

1 version recorded

Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Data source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China